📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. (2013)

First Author: Sale MJ

Attributed to: How does ERK1/2-dependent phosphorylation target BimEL to the proteasome? funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1042/bj20121212

PubMed Identifier: 23234544

Publication URI: http://europepmc.org/abstract/MED/23234544

Type: Journal Article/Review

Volume: 450

Parent Publication: The Biochemical journal

Issue: 2

ISSN: 0264-6021